İdiopatik Trombositopenik Purpuralı Bir Olguda Eltrombopag Kullanımı ile İlişkili İskemik İnme
Idiopatik trombositopenik purpura (ITP) tedavisinde kul- lanılmakta olan eltrombopag gibi trombopoetin reseptör (TpoR) agonistlerinin iskemik serebrovasküler hastalık oluşturma riski nadir görülmektedir. 5 yıldır ITP tanısı ile takip edilen sağ hemiparezi ve afazi kliniği ile acil servi- se başvuran hastaya yapılan tetkikler sonucunda iskemik serebrovasküler hastalık tanısı konuldu. Olguda serebro- vasküler hastalığın etyolojisi eltrombopag ile ilişkilendiril- di. Bu olgunun nadir görülmesi nedeniyle literatür eşliğin- de tartışıldı.
An Ischemic Stroke Related to Eltrombopag Use in a Patient with Idiopathic Thrombocytopenic Purpura
Thrombopoetin receptor agonists like eltrombopag, used for Idiopathic Thrombocytopenic Purpura treatment rarely cause to the ischemic cerebrovascular disease. In this re- port, a patient, have been followed by ITP diagnosis for 5 years, admitted to the emergency service for right hemi- paresis and aphasia. It was diagnosed as ischemic cere- brovascular disease. Etiology of patients cerebrovascu- lar event was associated with eltrombopag. Because of this rare seen situation, it was argued by in the light of the literature.
___
- 1. Chen YC, Wu JS, Yang ST, et al. Stroke, angiogenesis and phytochemicals. Front Biosci 2012; 4:599-610. 2. Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New Engl J Med 2007; 357:2237-2247. 3. Park HK, Lee SH. Ischemic stroke associated with immune thrombocytopenia: lesion patterns and characteristics. Neu- rol Sci 2014; 35:1801-1806 4. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune throm- bocytopenia in the United Kingdom General Practice Re- search Database. Haematologica 2010; 95:1167-1175. 5. Aoki T, Harada Y, Matsubara E, et al. Thrombopoietin recep- tor agonists in refractory immune thrombocytopenia: dif- ferential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Theraps 2012; 37:729-732. 6. Norgaard M: Thrombosis in patients with primary chronic immune thrombocytopenia. Thrombosis research. 2012; 130:74-75. 7. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin recep- tor agonist. Blood 2007; 109:4739-4741. 8. Catala-Lopez F, Corrales I, Martin-Serrano G, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin 2012; 139:421-429. 9. Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013; 109:676-683. 10. Andic N, Gunduz E, Akay OM, et al. Cardiac and pulmo- nary thrombosis during multidrug treatment in an idio- pathic thrombocytopenic purpura patient. Platelets 2014; 25:69-70 11. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393-402. 12. Tomiyama Y, Miyakawa Y, Okamoto S, et al: A lower start- ing dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012; 10:799-806.